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Abstract | Some Ru complexes have extremely promising anticancer or antibacterial properties, but their 10 
poor H2O solubility and/or low stability of many Ru complexes in aqueous solution under physiological 11 
conditions and/or metabolic/biodistribution profile prevent their therapeutic use. To overcome these 12 
drawbacks, various strategies have been developed to improve the delivery of these compounds to their 13 
target tissues. The first strategy is based on physical encapsulation of Ru complexes in carriers, such as 14 
polymeric micelles, microparticles, nanoparticles and polymer–lipid hybrids, which enabled the delivery 15 
and controlled release of the active Ru drug candidate. The second strategy involves covalent 16 
conjugation of the ruthenium complex to a polymer to give a prodrug that can be converted to the active 17 
drug at a more controllable rate. In this Review, we provide an overview of recent developments in 18 
polymer encapsulation of Ru complexes for biological and medicinalapplications, and place particular 19 
emphasis on the role of the polymer in the delivery carriers. 20 
  21 
[H1] Introduction 22 
Platinum-based drugs have dominated the field of medicinal inorganic chemistry since the discovery of 23 
the biological activity of cis-[PtCl2(NH3)2] (cisplatin) in the late 1960s and its approval for the treatment 24 
of some types of cancer by the US Food and Drug Administration (FDA) in 19781. Large doses of 25 
cisplatin are required to induce a therapeutic effect against different types of cancers. The dosage leads 26 
to various adverse effects for patients because cisplatin exhibits low selectivity towards cancer cells and 27 
has a short half-life in the blood. Moreover, some cancer cells are intrinsically resistant to cisplatin or 28 
can aquire resistance through an increased rate of repair of DNA intrastrand crosslinks2. Other Pt-based 29 
drugs, such as oxaliplatin and carboplatin, have been approved for therapeutic use, but have adverse 30 
effects (such as neurotoxicity and/or ototoxicity) similar to those of cisplatin. Alternative (metal-based) 31 
compounds with new mechanisms of action are therefore needed to avoid the problem of resistance to 32 
Pt-based drugs. Over the past two decades, Ru(II) and Ru(III) complexes have been intensively 33 
investigated in medicinal chemistry as anticancer and antibacterial agents3–8, enzyme inhibitors9–11, 34 
photosensitizers in photodynamic therapy12–15, and immunosuppressants16, and in biology as 35 
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luminescent probes (for imaging and the detection of biomolecules and cellular compartments17–20). 36 
Although the cytotoxicity of Ru complexes has been known since the mid-1950s21, the therapeutic 37 
potential of Ru complexes was only recognized in the mid-1980s following the publication of Clarke’s 38 
‘activation by reduction’ hypothesis for the molecular mechanism of Ru(III) complexes22. Under 39 
physiological conditions, Ru can exist in +II, +III and/or +IV oxidation states,23 each of which is 40 
stabilized by different coordination environments. The most common forms are 18e− Ru(II) species — 41 
either pseudo-octahedral complexes or pseudo-tetrahedral complexes featuring an η6-arene and three 42 
other donors. Ru(IV) complexes are typically highly soluble in H2O and often feature oxo, carboxylatoor 43 
sulfido ligands. In general, Ru(III) complexes appear to be less toxic than Ru(II) and Ru(IV) complexes24. 44 
Nevertheless, the potentials of the Ru redox couples are sensitive to the ligand environment and are 45 
readily accessed under physiological conditions, such that interconversion between the different 46 
oxidation states can be fast in vivo. Indeed, Ru(IV) or Ru(III) can be reduced to Ru(II) by biological 47 
reductants (such as ascorbate, glutathione and single-electron-transfer proteins), and Ru(II) can be 48 
oxidized to Ru(III) or Ru(IV) by biological oxidants (such as O2, H2O2 and cytochrome oxidase)24,25. 49 
 50 
The major strategy used in the development of Ru-based anticancer drug candidates is to administer a 51 
relatively inert high-valent compound that undergoes reduction in vivo to its active reduced form. This 52 
‘activation by reduction’ is most commonly seen with “biologically inactive” Ru(III) prodrugs that must 53 
be reduced to their Ru(II) form to be biologically active (for example, NAMI-A or KP-1339 complexes; 54 
FIG. 1), a process analogous to the activation of Pt(IV) prodrugs to (relatively) labile Pt(II) species. This 55 
is possible in the presence of high levels of biological reductants (for example, glutathione)26, such as 56 
in the hypoxic regions typically found in solid tumours27,28. If the active Ru(II) drug candidate leaves the 57 
tumour cell and moves to a more oxygenated environment, such as in healthy tissue, biological oxidants 58 
convert the Ru(II) conplex to its inactive Ru(III) form24. Mitochondrial and microsomal single electron 59 
transfer proteins can also reduce Ru(III) to Ru(II)29.. However this Ru reduction canbe also performed 60 
by transmembrane electron transport systems enabling the development of metallo-prodrug candidates 61 
with anticancer properties independent of the cell entry mechanism 23.  These Ru(II) complexes then 62 
undergo aquation, typically with displacement of one or two weakly bound donors such as halido ligands. 63 
For example, the Ru(II) arenes [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C; pta = 1,3,5-triaza-7-64 
phosphaadamantane; FIG. 1) and [Ru(η6-toluene)Cl2(pta)] (RAPTA-T)30–32, as well as the diamine–65 
arene species [Ru(η6-4-methylbiphenyl)(1,2-diaminoethane)Cl]PF6 (RM-175) and their derivatives33,34 66 
each have Cl− ligands that can be displaced by H2O. Substitution at a Ru(III) centre is also possible, and 67 
can afford Ru(III) aquation products and polynuclear species35–37.In both the reduction and aquation 68 
strategies to yield labile species, the medicinal efficacy of the ruthenium complex is directly related to 69 
the inherent reactivity of the Ru centre. Another strategy in drug design with Ru centres is to construct 70 
building blocks with three-dimension structures that have relative kinetic inertness for ligand exchange. 71 
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Here, the presence of Ru centre enable 3D geometries not available with organic chemistry. For example, 72 
the Ru(II) complex DW1 and its enantiomer DW2 mimic the shape of the alkaloid staurospaurine, and 73 
complexes thus also exhibit impressive kinase inhibition activity (targeting glycogen synthase kinase 3 74 
(GSK3) signalling) and cytotoxicity in human melanoma cancer cells38.  75 
 76 
The biological properties of Ru complexes — such as bioactivity, cellular uptake and intracellular 77 
distribution — depend, among others, on chemical properties such as electronegativity, chemical 78 
hardness, stereochemistry and net charge of the Ru centre. Ru drug candidates often feature strongly 79 
bound ligands, such as amine, phosphine, π-bound arenes and cyclopentadienyl derivatives. These are 80 
complemented by weakly bound ligands such as Cl− or RCO2−, which can be displaced by chelators or 81 
simply when an excess of competitive ligands is present. As is the case for reduced Pt derivatives, the 82 
lower-valent Ru(II) and Ru(III) complexes have favourable ligand exchange kinetics with O-donor and 83 
N-donor ligands. Ru complexes have several other advantages for biological and medicinal applications, 84 
including their usual low (or zero) toxicity to healthy tissues and their distinct mode of action. Indeed, 85 
they operate through different pathways to most Pt-based drugs, which typically only interact with DNA 86 
(BOX 1). Ru(II) and Ru(III) complexes have similar ligand exchange kinetics to the Pt(II) complexes 87 
used as antineoplastic drugs39. For small ligands such as H2O, the ligand exchange rate on the Ru centre 88 
is on the order of hours, which is similar to the timescale of cell division in many cell types40. 89 
 90 
Furthermore, Ru can bind biomolecules responsible for Fe solubilization and transport in plasma, 91 
including serum transferrin and albumin. Rapidly dividing cells, such as cancer cells, require more Fe, 92 
which leads to an upregulation of the number of transferrin receptors at the cell surface41. Consequently, 93 
Ru complexes have been proposed to preferentially target cancer cells over healthy cells42, which might 94 
explain their fairly low toxicity to the latter. This hypothesis is still the subject of debate43 because Ru 95 
complexes can enter cells by both transferrin-dependent and transferrin-independent mechanisms44-45.  96 
 97 
To date, no Ru drug candidates have been commercialized, although four Ru complexes are in various 98 
stages of clinical trials46. Trials of two well-known Ru-based drug candidates, trans-99 
ImH[RuIII(Im)(Me2SO)Cl4] (NAMI-A; FIG. 1; Im = imidazole) and trans-indazolium[RuIII(1H-100 
indazole)2Cl4] (KP1019) have been halted since NAMI-A showed limited efficacy in a phase II clinical 101 
trial47 and KP1019 exhibited poor solubility under physiological conditions in a phase I clinical trial48-102 
49. However, (pre-)clinical tests are being conducted on other Ru complexes: the trans-Na[RuIII(1H-103 
indazole)2Cl4] (KP1339), the Ru(II) polypyridyl TLD-1433 and RAPTA-C (FIG. 1). We note that by 104 
simply converting the indazolium salt KP1019 to its Na+ salt KP1339 affords a complex with greater 105 
H2O solubility that is in a phase IIA trial at the time of writing50-51. TLD-1433 just completed phase I 106 
clinical trial as a photosensitizer for photodynamic therapy (PDT) to treat bladder cancer52-53. RAPTA-107 
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C (FIG. 1) is currently in pre-clinical evaluation12. The testing of different Ru complexes as anticancer 108 
drug candidates in clinical studies is encouraging news for those wishing to develop Ru anticancer drugs 109 
as replacements for Pt-based drugs.  110 
 111 
Although the above strategies for Ru drug candidate design are sound, the poor solubility and/or low 112 
stability of many Ru complexes in aqueous solution under physiological conditions and/or 113 
metabolic/biodistribution profile limit their intravenous administration, and thus limits the amount of 114 
the complex that reaches the target tissue. Most Ru complexes studied to date have a short half-life in 115 
the circulation23,24 and a high overall clearance rate. Thus, although Ru complexes are undoubtedly 116 
promising drug candidates25, new drug delivery methods54-55 are needed in order for their therapeutic 117 
potential to be realized.  118 
 119 
[H1] Polymeric carriers for drug delivery 120 
The aim of nanomedicine is to create more effective and safer medicines through the identification of 121 
new drugs with novel mechanisms of action and the development of innovative drug formulations and 122 
delivery methods.Of the various nanomaterials available for drug delivery, macromolecules have 123 
attracted increased interest56. Our definition of macromolecules includes biomacromolecules, as well as 124 
synthetic polymers or dendrimers.. The properties of these macromolecules depend on the choice of 125 
repeating unit(s) (in particular, its structure), the ratio between hydrophilic and hydrophobic moieties in 126 
the polymer, and the length or size (molecular weight and molecular weight distribution) of the polymer 127 
and the resulting phase morphology. Encapsulation of a drug within a polymer is based on a ‘bottom 128 
up’ approach, in which the properties of each building blocks and Ru moiety are combined to prepare 129 
nanoscale materials. Self-assembling macromolecules provide several advantages for drug delivery. 130 
Although most of these macromolecules are typically not bioactive, the final biological application will 131 
determine the choice of polymer and, in particular, its degradation kinetics, which is directly linked to 132 
its biodegradability. Biocompatible polymers are by definition non-toxic and do not induce an immune 133 
response. Among biocompatible polymers, biodegradable polymers57 are mainly used for drug delivery, 134 
whereas non-biodegradable polymers as best suited for other applications, such as in bioimaging. A 135 
polymer is considered to be biodegradable if degradation occurs due to environmental action, which 136 
includes biological processes such as hydrolysis, oxidation and UV irradiation and/or biocatalytic 137 
processes involving, for example, bacteria, fungi and algae58. The definition of biodegradability that is 138 
used depends on the application of the polymer, such as biomedical or environmental applications. For 139 
example, biodegradation has been defined as enzymatic degradation and/or chemical decomposition 140 
associated with living organisms and their secretion products59. Biodegradable polymers for controlled 141 
drug delivery are typically degraded through hydrolysis by action of H2O molecules60 and/or by enzyme 142 
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cleavage61. Several factors influence the degradation rate of a polymer61, but the most important 143 
parameter is the kinetics of drug release62.  144 
 145 
Polymer architecture (for example, the presence of hydrolytic linkages, chain branching, 146 
stereochemistry), molecular weight and morphology (for example, the length of the repeating units, 147 
degree of crystallinity, degree of chain flexibility, and surface area) have a major effect on the observed 148 
degradation rate, as well as the surrounding conditions (for example, pH and temperature)61. For a 149 
medical device, the size, geometry and porosity of the polymer are also important factors63.  150 
 151 
The chemical functionalities in the repeating unit or units and the corresponding polymer may confer 152 
responsiveness to different stimuli, such as physical stimuli (for example, ionic strength), chemical 153 
stimuli (for example, hydrolysis or pH), biochemical stimuli (for example, enzymes) or environmental 154 
stimuli (for example, light or temperature), which can lead to the triggered release of a biologically 155 
active compound.  156 
 157 
Hierarchically ordered and complex architectures can be obtained according to the ratio of hydrophilic 158 
and hydrophobic moieties, as well as the presence of directional short and/or large non-covalent 159 
interactions. Monomers and their corresponding self-assembled polymers can form various 1D, 2D or 160 
3D architectures, such as rods (linear); thin films (lamellar); nanoparticles, microparticles, micelles, 161 
vesicles and polymer–lipid hybrids (spherical); and worm-like micelles, nanotubes or hydrogels (3D-162 
crosslinked networks). Self-assembly is driven by multiple types of interactions  such as strong 163 
hydrophobic or electrostatic interactions, hydrogen bonding, π–π stacking, metal–ligand coordination 164 
and stereocomplexation, or their synergistic associations. In contrast to covalent polymers, 165 
supramolecular polymers assemble by non-covalent and dynamic interactions. The self-assembled 166 
polymers in smart materials can self-heal or adapt their architecture in response to a small change of 167 
environment. The dynamic nature of self-assembly is responsible for the reversible nature of self-168 
assembly and stimuli-responsiveness. In the case of delivery systems, the biologically active compound 169 
can be delivered in a triggered64-65 and controlled66-67 way that reduces adverse effects. By limiting the 170 
drug dose and ensuring the drug efficiently targets specific organelles, it can be possible to restrict drug 171 
resistance68-69. The principle challenge in the design and construction of self-assembled macromolecular 172 
systems is ensuring their stability, a task that requires precise control of the balance between attractive 173 
and repulsive forces.  174 
 175 
Finally, the surface of the polymer can be decorated with recognition motifs (such as small biomolecules 176 
or peptides) to increase the specificity of targeting to organelles or diseased tissues. The effect of 177 
vectorization of macromolecular delivery systems is not described in detail in this Review. Instead, we 178 
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focus our discussion on the effect of the polymer in macromolecular carriers on the passive targeting of 179 
diseased tissues (BOX 2). 180 
 181 
Ru complexes used in medicinal applications often have low H2O solubility on account of their 182 
hydrophobic organic ligands. This and other inherent drawbacks can be addressed by encapsulating the 183 
complexes in delivery systems — a promising approach that differs from the traditional solution that 184 
involves formulating a drug with diluents (referred to as excipients). Macromolecules physically protect 185 
Ru complexes from biological degradation (by hydrolysis or reaction with proteolytic enzymes, radicals, 186 
reductants or nucleophilic species) and/or photodegradation (UV solar light). Furthermore, the 187 
polymeric matrix limits the exposure of healthy tissues to the drug and shields the Ru complex from the 188 
immune system, thereby preventing its elimination through renal excretion70. 189 
 190 
A polymer carrier increases the targeted delivery of a small molecule drug by selectively accumulating 191 
in diseased tissues because of the enhanced permeability and retention (EPR) effect71-73. This effect 192 
results from the leaky, highly permeable vasculature and poor lymphatic drainage of these tissues (BOX 193 
2), resulting in the efficient extravasation of nanocarriers from the tumour vasculature and their retention 194 
in the tumour interstitium. The EPR effect also leads to the encapsulated drug having a greater half-life 195 
than the free drug in the bloodstream. In mice, the plasma half-life of most small-molecule drugs is less 196 
than 3 min, while drugs subject to the EPR effect have a half-life of 6 h or more74. A drug that exhibits 197 
an EPR effect in mice does not always also behave this way in humans75. In mice, tumour growth is 198 
limited to several weeks, whereas in humans’ tumours can grow over several years, such that a long 199 
time period is available for angiogenesis. Furthermore, the EPR effect varies with the type of tumour76, 200 
and new tools need to be developed to improve the efficiency of nanocarriers for the delivery of 201 
anticancer drugs76. 202 
 203 
Using a polymeric carrier should improve the efficacy and the targeting efficiency of a biologically 204 
active compound by increasing its availability, which could potentially alleviate the adverse effects of 205 
Ru complexes. Furthermore, macromolecular delivery systems incorporating multiple compounds 206 
enable multi-action and multi-target delivery or the possibility to combine therapeutic and diagnostic 207 
tools to afford theranostic agents. For example, two Ru compounds for chemotherapy and PDT can be 208 
delivered simultaneously. Alternatively, as diagnostic tools, a bioactive compound can be delivered in 209 
association with a Ru dye for imaging. Despite the numerous advantages of macromolecular delivery 210 
systems, the nanoarchitectures constructed from polymers are not always completely biocompatible. 211 
Indeed, the polymer and/or its degradation product(s) can be mildly toxic, such that extensive in vitro 212 
and in vivo testing is required to minimize this toxicity.  213 
 214 
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Two major strategies have been used to encapsulate Ru complexes in macromolecular systems — 215 
physical encapsulation and covalent conjugation (FIG. 2). Physical encapsulation relies on non-covalent 216 
interactions between the Ru complex and the polymeric matrix. Covalent conjugation of the Ru complex 217 
to the polymer affords a well-defined metallopolymer prodrug. In this Review, we provide an overview 218 
of polymers used to encapsulate Ru complexes for biomedical applications. We discuss the importance 219 
of the relationship between the properties of the polymer and the final Ru-containing polymeric carriers. 220 
The polymeric systems are classified on the basis of the type of interaction between the Ru complex and 221 
the polymer (physical entrapment or covalent conjugation) and according to the structure of the resulting 222 
microparticles or nanoparticles. Of note, Ru-containing nanohybrids, which are defined here as hybrids 223 
comprising Ru complexes and a non-polymer inorganic nanomaterial (such as Au nanostructures), 224 
porous nanostructures (such as zeolites), SiO2 nanostructures, quantum dots and C nanotubes are not 225 
covered in this Review. In such species, the polymer only has a minor effect on the final properties of 226 
nanohybrids, which are in any case reviewed elsewhere55,77. 227 
 228 
[H1] Physical encapsulation	229 
Physical encapsulation of Ru complexes in polymeric carriers is similar to the encapsulation of organic 230 
biologically active compounds78. When designing polymers to serve as efficient Ru carriers, one must 231 
consider several features of the polymer, including size, charge, structure and degradation kinetics. 232 
 233 
[H2] Polymer size 234 
The size of a nanocarrier directly affects the efficiency with which Ru complexes target diseased tissues. 235 
Therapeutically-relevant Ru complexes are small and can passively diffuse out of capillaries into the 236 
interstitial fluid, leading to undesired adverse effects. Tumour tissues are structurally distinct from 237 
healthy tissues (BOX 2), and these differences have been exploited to design efficient macromolecular 238 
delivery systems. Although the diameter of a carrier intended for biological applications is typically in 239 
the range 10 – 1000 nm, the carrier’s diameter should ideally not exceed 300 nm in order to enable the 240 
EPR effect (BOX 2) to ensure efficient passive targeting of tumour tissues79. Directly linked to carrier 241 
size, the molecular weight of individual solvated biodegradable polymer chains should be >40 kDa to 242 
ensure an efficient EPR effect and a long circulation time without renal excretion70. In the case of 243 
individual solvated non-biodegradable polymer chains,80 the molecular weight is limited to 40 kDa to 244 
ensure renal elimination. However, for nanocarriers based on the assembly of polymer chains (such as 245 
micelles or liposomes), it is not possible to estimate the minimum molecular weight for individual 246 
polymer chains owing to the variety of polymer structures and assemblies. 247 
 248 
[H2] Polymer charge 249 
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The surface charge of nanocarriers affects their stability and targeting efficiency. Although a positively 250 
charged surface favours cell adhesion for rapid endocytosis, a neutral or negative surface charge is 251 
preferred because of lower non-specific adsorption of proteins and non-specific phagocytosis by cells 252 
of the reticuloendothelial system (RES)81. 253 
 254 
[H2] Polymer chemical structure 255 
Depending on the solubility of the Ru complex in the polymeric matrix, the chemical structure of a 256 
biocompatible polymer should be chosen to ensure chemical and physical compatibility between the 257 
polymeric carrier and the Ru complex. Furthermore, a suitable preparation method should be selected 258 
to ensure sufficient loading of the Ru complex. The carrier should ideally have a well-defined structure 259 
to avoid phase separation, which can lead to inhomogeneity and lower biological efficicacy. The 260 
integrity of the carrier nanostructure must also be maintained after encapsulation of the Ru complex. 261 
Because many medicinally-relevant Ru complexes have a charge, it is necessary to control the physical 262 
interactions (mostly hydrophobic or electrostatic interactions) between the polymeric matrix and the Ru 263 
complex. A judicious choice of nanocarrier architecture must be made, and this involves selecting a 264 
suitable ratio of hydrophobic and hydrophilic domains and appropriately functionalizing the polymer 265 
with polarisable residues. 266 
 267 
[H2] Polymer biodegradability 268 
Depending on the biological application, the biodegradability of the polymer as well as its composition 269 
must be controlled to regulate the disintegrationof the polymeric nanocarrier and the subsequent release 270 
of the Ru complex. Except for a few applications, such as bioimaging or the controlled release of a 271 
therapeutic gas, most delivery systems require biodegradable polymers. The use of non-biodegradable 272 
polymers is not always linked to the problem of accumulation. These polymers must be eliminated by a 273 
furtive way. The use of non-biodegradable copolymers allows one to ameliorate polymer properties 274 
(such as hydrophilicity, stability), but the elimination of these species can occur without the release of 275 
a pharmaceutically active compound. In the case of biodegradable polymers, the initial hydrolysis of 276 
cleavable links leads to the release of surface-adsorbed Ru complexes, after which the residual polymer 277 
biodegrades slowly and releases the remaining payload in a controlled fashion over the course of weeks 278 
to years82. This fast initial release is termed the ‘burst effect’ and should be minimized in order to 279 
maximise targeting efficiency.83-84 The rate at which a Ru complex is released from a biocompatible 280 
polymers depends on multiple factors, such as the concentration gradient of the Ru complex in the 281 
polymeric matrix, the mobility and diffusion of the Ru complex in the nanocarrier, the polymer 282 
degradation rate (which is related to polymer properties such as the composition, molecular weight, 283 
molecular-weight distribution, composition, crystallinity and chemical structure). Ru complexes should 284 
be released by diffusion and/or through biochemical degradation of biodegradable polymers. Depending 285 
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on the structure of the cleavable functionality, biodegradation can be catalysed in the acidic environment 286 
characteristic of diseased tissues. Different degradation kinetic profiles can be obtained depending on 287 
the regioregularity or stereoregularity of the polymer sequence in the copolymers85. The overall rate of 288 
degradation for alternating copolymers is slower than for random counterparts and alternating 289 
copolymers degrade with a uniform linear degradation profile, which gives access to a homogeneous 290 
mixture after the first burst stage leads to an initial rapid drop in weight. 291 
 292 
The principal advantage of physical entrapment is that the integrity of the Ru complex (that is, the 293 
geometry, oxidation state and stereochemistry of the Ru centre) is conserved. However, the stability of 294 
the nanocarrier and its preservation for prolonged periods after synthesis are important challenges 295 
associated with using physical encapsulation. A balance must be found between a carrier that is too 296 
stable (and does not correctly release the Ru complex) and one that is too unstable (and does not reach 297 
the biological target or prematurely disassembles). 298 
 299 
[H1] Polymer micelles	300 
Polymer micelles were first used as drug delivery carriers in the 1980s86-87. Polymeric micelles are self-301 
assembled nanosize colloidal particles that are obtained from amphiphilic block copolymers, usually in 302 
aqueous medium, and are generally larger than dendrimers and liposomes. Spherical polymeric micelles 303 
are typically 10 – 100 nm in diameter88 and have an extremely narrow size distribution. This size can 304 
increase when serum proteins adsorb, sometimes rendering the particles too large for renal excretion89. 305 
In addition to the archetypal spherical shapes, these micelles can self-assemble into cylindrical and 306 
flexible structures (~40 nm in width and 20 – 40 μm in length)90-91. 307 
 308 
Above the critical micelle concentration (CMC), single chains of amphiphilic polymers self-assemble 309 
into micelles to minimize the contact between the hydrophobic block and the aqueous medium92. The 310 
CMC is an important parameter in evaluating the stability of micelles. In general, the CMC for polymers 311 
(1–10 μM−1) is lower than that for low molecular weight surfactants (mM-1 range)88. A low CMC induces 312 
greater thermodynamic and kinetic stability in polymer micelles than in surfactant-based micelles. In 313 
principle, the formation of micelles is driven by a decrease in free energy. Hydrogen bonding between 314 
H2O molecules and the hydrophilic segment, as well as minimization of contact between the 315 
hydrophobic segment and the aqueous medium, enable the formation of a core–shell micelle by entropy-316 
driven microphase separation. 317 
 318 
Diblock copolymers are usually used to obtain core–shell micelle architectures. The outer shell is 319 
composed of the hydrophilic blocks to enable stable dispersion in aqueous environments. The 320 
hydrophilic shell protects the encapsulated Ru complex by minimizing adsorption of biocomponents 321 
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(such as protein) onto the surface of the micelle during circulation in the bloodstream or interaction with 322 
cellular membranes. The inner core is formed from the hydrophobic block and is stabilized by 323 
hydrophobic interactions. In the core–shell architecture, the hydrophobic segment provides a space, 324 
termed a reservoir, for the physical encapsulation of hydrophobic Ru complexes. Longer hydrophilic 325 
segments are used in amphiphilic diblock copolymers to obtain spherical micelles. The limited kinetic 326 
stability of micelles can be a problem because there is a dynamic equilibrium between the self-assembled 327 
micelle and the bulk phase93. This equilibrium depends on temperature, polymer concentration, the pH 328 
and ionic strength of the biological medium. For biological applications, micelles must be stable during 329 
transport to the biological target but the equilibrium must shift when reaching the target region, so as to 330 
ensure efficient release of the Ru complex. In addition, the stability of micelles is highly dependent on 331 
the glass transition temperature (Tg) of the hydrophobic polymer block that constitutes the core of the 332 
micelle. 333 
 334 
The ratio of hydrophilic to hydrophobic block size can be controlled during synthesis to obtain micelles 335 
of a desired size. The physicochemical properties of the amphiphilic polymer determine the choice of 336 
polymer micelle preparation method, which include emulsion–solvent evaporation94, 337 
nanoprecipitation95, dialysis96 and a thin-film method97. The size and morphology of micelles can be 338 
modulated by the choice of copolymer molecular weight, block length, composition and the preparation 339 
method. The maximum achievable drug loading depends on the chemical affinity between the Ru 340 
complex and the hydrophobic polymer block as well as the preparation method98. 341 
 342 
Physical studies of dendrimers indicate that these highly branched monodisperse macromolecules exist 343 
in solution as unimolecular micelles — motifs that can be used as potential delivery systems99-100. In 344 
contrast to linear, cross-linked or low-branched polymers with a narrow molecular weight distribution, 345 
dendrimers have a precise molecular weight that is optimal for reproducible pharmacokinetic studies. 346 
The high density of functional groups on the surface of dendrimers allows higher drug loading and well-347 
defined structures to be obtained. 348 
 349 
[H1] Microparticles and nanoparticles 350 
Spherical polymeric microparticles and nanoparticles (FIG. 2) are defined as matrix-type solid colloidal 351 
particles in which biological species are dissolved, entrapped, encapsulated or absorbed to the polymer 352 
matrix101. These particles are typically larger than micelles (usually 100–200 nm in diameter). 353 
Homopolymers, such as poly(ε-caprolactone) (PCL), poly(lactic acid) (PLA) and poly(glycolic acid) 354 
(PGA) and the corresponding copolymer poly(lactid-co-glycolic)acid (PLGA), are used to prepare solid 355 
polymer nanoparticles102. Self-assembly of these polymers is based on hydrophobic or electrostatic 356 
interactions; for example, in ionotropic gels, the cations or anions link the different polymer strands. 357 
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However, the hydrophobic surfaces of these particles are not suitable for long-term circulation in the 358 
blood (BOX 2). For this reason, the surface of these particles must be coated with hydrophilic polymers 359 
to ensure that they are invisible to the reticuloendothelial system (RES). Another solution is the use of 360 
an amphiphilic diblock copolymer containing a polyethylene glycol (PEG) segment102 (BOX 2). 361 
Nanoparticles can be prepared using several preparation methods, although nanoprecipitation remains 362 
the most popular method102.  363 
 364 
[H2] Biodegradable polymers	365 
All biodegradable polymers have hydrolytically or proteolytically labile bonds in their backbone and/or 366 
in their crosslinker (FIG. 3). No additional functionalization is necessary for the use of these polymers 367 
for delivery applications. They break down into smaller polymer fragments (which can sometimes even 368 
be common metabolites in the body) that can be readily metabolized and cleared from the body, ensuring 369 
that they are non-toxic and non-immunogenic.  370 
 371 
The range of natural biodegradable polymers suitable for the encapsulation of Ru complexes is 372 
unfortunately rather small because of limitations regarding their preparation. In addition, the presence 373 
of several identical functional groups in the lateral pendants of these polymers makes selective 374 
functionalization difficult. However, naturally occuring polysaccharides are interesting candidates as 375 
drug carriers because they mimic the extracellular matrix, which is involved in tissue regrowth and 376 
repair. For example, chitosan, a component of crustacean exoskeletons, is a polycationic polysaccharide 377 
that consists mostly of β-(1→4)-linked D-glucosamine units (FIG. 3). Chitosan is H2O-soluble in mildly 378 
acidic solutions (pH < 6.3) because its amine groups become protonated. In addition to its antimicrobial 379 
properties103-104, chitosan has low O2 and CO2 permeability and acts as a temporary barrier against 380 
photoluminescence quenchers. Tris(2,2′-bipyridyl)ruthenium(II) ([Ru(bpy)3]2+) embedded in a 381 
homogeneous and transparent thin film of chitosan has been used as a temperature-sensitive 382 
luminescence sensor105. The biocompatibility of chitosan and the red emission (λex = 455 nm, 383 
λem = 605 nm) of the Ru complex, at which the maximum penetration of biological tissue by light is 384 
possible, makes this a promising sensor for biological sensing applications. 385 
 386 
Alginate is a polysaccharide consisting of (1→4)-linked residues of β-D-mannuronic acid and α-L-387 
gluronic acid in varying proportions and sequences along the chain (FIG. 3). Alginate has been used in 388 
various therapies106, such as chemotherapy or cell-based therapy (the use of living cells as therapeutic 389 
agents107-108). For example, deprotonating the carboxylic acids on the polymer and introducing  divalent 390 
cations lead to ionotropic gelification and the formation of alginate beads. The polyanion can 391 
encapsulate catonic Ru–nitrosyl complexes such as {Ru[2-(4-chlorobenzylideneamino)-4-392 
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nitrophenol](PPh3)2(NO)}+, a photolabile species that controllably releases of NO in vitro after 393 
irradiation with visible light109. 394 
 395 
Despite being non-toxic, the limited available functionalities and high cost of natural biodegradable 396 
polymers have resulted in synthetic polymers being more frequently used as delivery carriers. The 397 
biodegrading of most synthetic polymers proceeds through the hydrolytic cleavage of ester bonds, as is 398 
the case for poly(lactic acid) (PLA, FIG. 3), poly(glycolic acid) (PGA) and the corresponding 399 
copolymers poly(lactid-co-glycolic)acid) (PLGA), poly(ε-caprolactone) (PCL). However, the presence 400 
of other chemical functionalities, such as anhydrides, ortho-esters, phosphoesters, phosphazenes and 401 
cyanoacrylates (containing a C–C bond that is hydrolytically unstable due to the proximity of cyano 402 
electron withdrawing groups) also make a polymer degradable. The degradation of PLA and PLGA 403 
affords acidic products that catalyse further degradation of the polymers. In contrast, hydrolysis of the 404 
semicrystalline polymer PCL does not afford acidic by-products, such that PCL has a low degradation 405 
rate and is useful for the preparation of long-term devices. 406 
 407 
Aliphatic polyesters, such as PLA, PGA and PLGA (FIG. 3), are the most commonly used biodegradable 408 
polymers in biological applications, owing to their controlled degradation (weeks to years) by hydrolysis 409 
in vitro and in vivo110-112. The biocompatible degradation products of these polyesters — lactic acid and 410 
glycolic acid — are non-toxic and are metabolized to give CO2 and H2O as benign by-products86, 113. All 411 
these polymers [have been approved as therapeutic drug carriers by the US Food and Drug 412 
Administration (FDA)114. However, these polymers are hydrophobic, such that the resulting polymeric 413 
nanoparticles must be stabilized in aqueous medium by the addition of amphiphilic polymers as 414 
surfactants in single H2O–oil emulsion.  415 
For example, KP1019 has been encapsulated in PLA nanoparticles (~164 nm in diameter) in the 416 
presence of a non-ionic surfactant such as the poloxamer (a type of polyether, see below) Pluronic® F-417 
68 or a polysorbate (an ethoxylated sorbitan esterified with hydrophobic acid) such as Tween 80. The 418 
entire assembly is prepared by single oil-in-H2O emulsion115, and in contrast to Pluronic® F-68, Tween 419 
80 prevents drug precipitation at drug doses that are necessary for in vivo use. It is thought that KP1019 420 
conjugation to Tween 80 involves substitution of a Cl− ligands for a moderately basic oxygenic group 421 
in Tween 80 atom, with the resulting linkage being more stable that is the case for Pluronic® F-68, which 422 
only has ethereal O atoms. On binding Tween 80, KP1019 complexes not only undergoes ligand 423 
substitution but also reduction, with electron paramagnetic resonance spectroscopic data being 424 
consistent with the paramagnetic Ru(III) centres being converted to diamagnetic Ru(II) sites, whose exact 425 
structure is unknown. Indeed, the autoxidation of polysorbates such as Tween 80 in the presence of 426 
transition metals is accompanied by the simultaneous reduction of the metal ion116. Reduction of the 427 
Ru(III) centre is accompanied by a colour change (from brown to deep green) and is associated with 20-428 
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fold higher cytotoxicity compared with free KP1019116. Of note, this present biodegradable nanoparticle 429 
approach has been applied to Ru-mediated PDT. The method was enabled by the efficient loading (~50–430 
60%), by nanoprecipitation, of a [RuII(1,10-phenanthroline)3]2+ photosensitizer, in which the ligands are 431 
decorated with hydrophilic triethyleneglycol-functionalized-5-fluorene groups, into PLGA 432 
nanoparticles (100 nM) in the presence of Pluronic® P-188117. The resulting nanoparticle was stable and 433 
less toxic than the free photosensitizer, releasing only a small amount of photosensitizer while in the 434 
dark under physiological conditions. After irradiation with 740 nm light, more of the two-photon-excited 435 
photosensitizer was released, such that a substantial level of singlet oxygen (1O2) could be generated to 436 
kill C6 glioma cells.  437 
 438 
H2O-soluble Ru–NO complexes have also been encapsulated in PLGA nanoparticles and microparticles 439 
using a double emulsion preparation (H2O–oil–H2O). Thus, Ru nitrosyls featuring amine co-ligands such 440 
as NH3, cyclam or N,N,N′,N′-ethylenediaminetetraacetate, can be encapsulated in PLGA 441 
microparticles118 (up to 1,600 nm in diameter) or nanoparticles119 (220–840 nm in diameter). The 442 
primary H2O–oil emulsion, consisting of the NO-donor Ru complex solubilized in aqueous polyvinyl 443 
alcohol (PVA) aqueous solution and emulsified in an organic phase containing PLGA, was transferred 444 
into an aqueous PVA solution to produce the final H2O/oil/H2O emulsion. In these  cases, a low loading 445 
efficiency (25–32%) was observed and the PLGA matrix absorbed light in the same spectral region as 446 
the embedded Ru–NO complexes, which are thus less liable to undergo photoactivation and exert their 447 
biological action. Despite the lower phototoxicity of encapsulated versus free complexes, the latter show 448 
improved targeting of tumour cells. Trans-[Ru(NO)(cyclam)Cl](PF6)2 in PLGA nanoparticles killed 449 
53.8 ± 6.2% of cells and trans-[Ru(NO)(NH3)4(py)](BF4)3 in PLGA microparticles killed 63 ± 3% of 450 
cells. The size of the PLGA particles apparently does not influence the drug release profile, which 451 
features an initial burst in the first 24 h followed by a slow release due to the hydrolytic degradation of 452 
PLGA, which resulted in the gradual release of NO through pores in the particle surface. Although the 453 
time required for complete degradation of the PLGA matrix was not reported, it is likely that 454 
microparticles had longer release times than nanoparticles. A double emulsion preparation was also used 455 
to efficiently encapsulate the related complex trans-[RuCl([15]aneN4)NO]Cl2, which could be loaded at 456 
a level of 51.0 ± 5.0% in spherical PLGA nanoparticles (830 ± 18 nm in diameter)120. 457 
 458 
Unconventional inverse non-aqueous emulsion was necessary to encapsulate the polar NO complex 459 
{[(N,N′-1,2-phenylene)bis(1-methyl-1H-imidazole-2-carboxamide)]Ru(NO)Cl}, which is poorly 460 
soluble in H2O and organic solvents. The complex was hosted in nanoparticles consisting of gelatin, 461 
PLA, poly(vinyl formal) (PVF) and poly(ethyleneterephthalate) (PET) using amphiphilic 462 
poly[(butylene-co-ethylene)-b-(ethylene oxide)] as a surfactant and hexafluoroisopropanol as a 463 
solvent121. Localized in the PVF domain, the Ru complex released NO only slowly after photo-464 
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irradiation, because the host absorbs light access and mass transfer within the polymeric matrix is 465 
hindered. It is thought that using hexafluoroisopropanol (a dense liquid) as the solvent affords densely 466 
packed polymeric nanoparticles (with diameters < 300 nm), from which the Ru complex cannot escape, 467 
even after NO photorelease. The use of such unconventional emulsion preparations could be interesting 468 
for the preparation of nanocarriers with slow release of encapsulated biological compounds. 469 
 470 
It is also possible to encapsulate a Ru complex, such as [(N,N′-(1,2-phenylene)bis(1-methyl-1H-471 
imidazole-2-carboxamido)Ru(NO)Cl], by electrospinning poly(L-lactide-co-D/L-lactide) to afford a 472 
nanofibrous non-woven composite122. What resulted was a bimodal distribution: ~650 nm diameter 473 
fibres (10wt% complex loading) and ~950 nm fibres (25wt% complex loading). After exposure to low-474 
intensity UV-A light, a low continuous amount (0.08 ± 0.02%) of NO the was immediately released, 475 
with only asmall amount of NO being leached (0.26± 0.10%) after five days122. Relative to polyesters, 476 
polyamides are degraded more slowly because amides are generally more resistant to hydrolysis. 477 
Polyamides have been used as protective shells for a Ru(II) photosensitizer bearing three disulfonated 478 
4,7-diphenyl-1,10-phenanthroline ligands. The nanoparticles (hydrodynamic radius 20–25 nm) were 479 
constructed from polyacrylamide (PAA) or amine-functionalized polyacrylamide (AF-PAA)123 matrices 480 
that prevent quenching of photogenerated 1O2, thereby allowing  gas diffusion in the exterior of the 481 
nanoparticle. The Ru photosensitizer leached from the AF-PAA-based nanoparticles only very slowly 482 
(over a period of days) owing to the electrostatic interactions between ammonium groups on the host 483 
and the sulfonates on the Ru complex. This system appears promising for the targeted production of 1O2 484 
in PDT applications.  485 
 486 
[H2] Non-biodegradable or slowly-biodegradable polymers  487 
Biocompatible non-biodegradable polymers have only few biological applications, including 488 
bioimaging, theranostics and the controlled release of a biologically active gas (CO or 1O2 for PDT). 489 
These applications have mostly used commercially available (or easy-to-prepare) diblock or triblock 490 
copolymers that serve as a protective shell against biological species (for encapsulated gas-donor Ru 491 
complexes), light, 1O2 or radicals (for encapsulated photosensitizers or phosphorescent Ru complexes). 492 
Most of these copolymers contain one polymer segment that is hydrophilic on account of carboxylic 493 
acid groups. The gas permeability and the photophysics of the polymeric matrices seem to be the 494 
principal properties to control for the efficient design of these delivery systems. 495 
 496 
The CO-releasing molecule CORM-2 (4.1wt%, FIG. 1) was encapsulated in styrene–maleic acid 497 
copolymer micelles with a hydrodynamic diameter of 165.3 nm. These nanomicelles were bioactive for 498 
longer in vivo than the free Ru complex CORM-2, had a 35-fold longer half-life in circulation after 499 
intravenous injection in mice and showed selective accumulation in inflamed tissues124. In small doses, 500 
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CO has anti-oxidative and anti-inflammatory effects, and the slow release of CO here is desirable such 501 
that these micelles are drug candidates for diseases including ischaemia–reperfusion injury, bacterial 502 
and viral infections, hypertension and diseases (including inflammatory bowel disease) caused by 503 
reactive oxygen species (ROS) such as 1O2 and oxyl radicals. To improve the efficiency of 504 
photoactivable Ru complexes, they have been encapsulated in cross-linked polymer nanoassemblies and 505 
the influence of factors such as photoactivation, hydrophobicity, and solution ionic strength and pH, on 506 
complex loading and release studied. Cross-linked polymeric nanoassemblies based on 507 
poly(ethyleneglycol)–poly(aspartate) block copolymer (PEG–PASP) were also used to encapsulate 508 
three different cationic Ru complexes through electrostatic interaction with the carboxylate acid groups 509 
of the ASP core block125. The rate of Ru release from the PEG–PASP nanoassembly is highly dependent 510 
on the hydrophobicity of the complex and the solution ionic strength but surprisingly independent of 511 
pH. The Ru(II) polypyridyl {Ru(bipy)2[7-(hydroxymethyl)dipyrido[3,2-a:2′,3′-c]phenazine]}2+ is a PDT 512 
photosensitizer that has been encapsulated in block copolymers consisting of poly(N,N-513 
dimethylaminoethyl methacrylate) (PDMAEMA) as one segment and either poly(methyl methacrylate) 514 
(PMMA) or a statistical copolymer (PDMAEMA-co-PMMA) as a second segment.126. No release of the 515 
Ru complex from micelles with PDMAEMA-b-PMMA ( occurs in response to ultrasound, whereas Ru 516 
release from micelles with the block copolymer featuring PDMAEMA and PDMAEMA-co-PMMA 517 
segments occurs in response to ultrasound, reflecting the different core–shell structures of the different 518 
particles. 519 
Poloxamers are biocompatible non-ionic triblock copolymers with an ABA structure, comprising a 520 
hydrophobic central B block flanked by hydrophilic lateral A blocks127-129. The A block is poly(ethylene 521 
oxide) and the B block is poly(propylene oxide), and one can adjust the molar ratio (from 1:9 to 8:2) 522 
and molecular weight to tune the physicochemical properties of amphiphilic poloxamers, in particular 523 
gelation temperature and in vivo properties, such as their interaction with cells and membranes. The 524 
commercial poloxamers Pluronic® P-123 and Pluronic F-127 can self-assemble into spherical micelles. 525 
A bioprobe for high-resolution two-photon quantitative imaging of oxygen in aqueous media was 526 
obtained by encapsulating the commercial hydrophobic phosphorescent dye [Ru(4,7-diphenyl-1,10-527 
phenanthroline)3]2+ in the core of Pluronic® F-127 nanomicelles using hydrophobic interactions130. Based 528 
on the ‘collisional quenching’ process, the collision between O2 and an excited luminophore provides a 529 
non-radiative pathway for highly electronically excited species to relax, decreasing its phosphorescence 530 
intensity and lifetime131. The hydrophobic core of each nanomicelle permits the diffusion of O2 and hosts 531 
the phosphorescent dye, with the aqueous solubility of the assembly being dependent on the length of 532 
the hydrophilic tails. After self-assembly, it is possible to isolate by filtration only the nanomicelles 533 
larger than 5 nm, with small assemblies being less desirable because they can diffuse across the 534 
vasculature endothelium. The nanomicelle probes are stable for several months in H2O and for several 535 
hours in biological medium — long enough to make a two-photon quantification of O2 and perform 536 
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multiphoton microscopy. Furthermore, these nanomicelle probes are at least twice as sensitive as the 537 
free phosphorescent dye in H2O, although the O2-sensing response of the probes is dependent on 538 
temperature and solvent, such that calibrations are required for in vivo testing. The hydrophobic Ru 539 
dithiolate [Ru(p-cymene)(1,2-dicarba-closo-dodecarborane-1,2-dithiolato)] (FIG. 1), a complex 540 
investigated in boron neutron capture therapy (BNCT), has been encapsulated in the core of Pluronic® 541 
P123 core–shell nanomicelles to increase its H2O solubility and targeting of cancer cells132. The molar 542 
ratio A:B of the hydrophilic to hydrophobic domains for Pluronic® P123 is lower than for Pluronic® F-543 
127, such that the former has a larger nanomicelle core, with its estimated hydrodynamic diameter being 544 
7.8–21.4 nm and dispersity 0.04 according to dynamic light scattering measurements. The Ru complex 545 
has a lower anticancer activity after encapsulation, but the accumulation of the encapsulated Ru complex 546 
in A2780 (human ovarian) and A2780cisR (cisplatin-resistant human ovarian) cancer cell lines is 2.5-547 
fold higher than that of the free Ru complex. In A2780cisR cells, the encapsulated Ru complex remains 548 
sensitive to neutron irradiation, with the antiproliferative activity of these nanomicelles, at micromolar 549 
concentrations of Ru, being 1.4-fold higher than that of non-irradiated nanomicelles. 550 
 551 
[H1] Polymer-decorated liposomes and polymer–lipid hybrids  552 
Phospholipids and other low-molecular weight surfactants can self-assemble in aqueous medium to 553 
afford spherical vesicles consisting of one or more phospholipid bilayers. These vesicles are examples 554 
of liposomes and feature amphiphilic phospholipids consisting of a hydrophobic tail and a hydrophilic 555 
head group. Spherical liposomes contain a aqueous lumen delimited by a hydrophobic membrane. 556 
Hydrophilic biologically active compounds can be enclosed in the internal aqueous volume inside the 557 
spherical liposome, whereas lipophilic biologically active compounds can be incorporated in the lipid 558 
bilayer. Liposomes have been the most common type of nanocarriers for the targeted delivery of 559 
amphiphilic drugs for more than 50 years133. Polymer-decorated liposomes are obtained by coating 560 
preformed Ru complex-loaded liposomes with hydrophilic polymers, whereas polymer–lipid hybrids 561 
are obtained by inserting polymer chains (with a covalently bound Ru complex) into the lipid bilayer 562 
during the self-assembly of phospholipids134-135 (FIG. 2). We now describe the role of the polymer in 563 
polymer-decorated liposomes and polymer–lipid hybrids. 564 
 565 
[H2] Spherical polymer-decorated liposomes  566 
A drug can spend a longer time in circulation if loaded in a liposome coating with hydrophilic polymers, 567 
which confer ‘stealth’ on the liposome (BOX 2) by protecting it from normal clearance mechanisms. 568 
For example, the PDT photosensitizer [Zn(phthalocyanine)] and NO donor [Ru(tpy)(α-diimine)NO]3+ 569 
(tpy = 2,2′:6′,2′′-terpyridine) were encapsulated in 82 nm stealth liposomes consisting of L-α-dipalmitoyl 570 
phosphatidylcholine (DPPC) and cholesterol coated with PEG2000 (50–60% loading)136. On irradiation 571 
with visible light, [Zn(phthalocyanine)] induces ROS formation and NO is simultaneously released from 572 
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the Ru complex. Absorption and fluorescence quenching studies confirmed that hydrophobic 573 
[Zn(phthalocyanine)] can be incorporated into the slightly deformed lipid bilayer whereas the Ru 574 
complex can move between the internal and external liposome environments. The different localizations 575 
of the active compounds can be explained in terms of the electrostatic interactions between the cationic 576 
Ru complex and the anionic phospholipid head groups. In contrast, charge-neutral [Zn(phthalocyanine)] 577 
predominantely engages in hydrophobic interactions with the organic tails. After photoactivation, these 578 
stealth liposomes reduce the viability of mouse B16-F10 melanoma cells by ~95% in vitro. Using the 579 
same guests, one can form ultradeformable liposomes by adding the non-ionic surfactant 580 
polyoxoethylene (20) sorbitan monolaurate (polysorbate 20; also known as Tween 20) to the surface of 581 
liposomes137-138.  582 
 583 
[H2] Polymer–lipid hybrids 584 
It is possible that not all Ru complexes correctly enter in liposomes, for example because the complexes 585 
instead interact favourably with the surface of the polymer–lipid hybrid. To address this, the surface of 586 
liposomes or polymer–lipid hybrids can be coated with amphiphilic Ru complexes. The complexes must 587 
be functionalized with a hydrophobic segment to be correctly incorporated in the lipid membrane during 588 
the self-assembly of phospholipids. A library of nucleolipid nanovectors consisting of uridine or 589 
thymidine nucleobases was designed and synthesized to encapsulate amphiphilic Ru complexes139 (FIG. 590 
S1a). One or two oleic acid residues attached to the secondary OH of ribose serve as a motif for insertion 591 
into the lipid monolayer or multi-layer in aqueous solution, and a hydrophilic oligoethylene glycol chain 592 
at the 5′ end contributes to the stealth properties of these nanovectors. A pyridine motif was inserted in 593 
order to give a complex analogous to Azi-Ru (FIG. 1), a species similar to the anticancer drug candidates 594 
NAMI-A and KP1019. The Ru complexes remain hidden among the phospholipid head groups at the 595 
surface of the liposomes (FIG. S1a). The position of the Ru complexes as well as the liposome membrane 596 
composition (consisting of the zwitterion palmitoyl-2-oleyl-sn-glycero-3-phosphocholine (POPC) or the 597 
cationic lipid 1,2-dioleyl-3-trimethylammoniumpropane chloride (DOTAP)) effectively slow the 598 
hydrolysis by retarding the ligand exchange process140-141, which is consistent with the high kinetic 599 
stability of these formulations, which persist for months. Incorporating Ru complexes into a 600 
phospholipid membrane at levels below the loading limit induces only a small deformation in the 601 
membrane and only minimally affects the morphology of the liposomes. After encapsulation of a 602 
uridine-based nucleolipid HoUrRu (FIG. S1a) in POPC-based or DOTAP-based liposomes, the 603 
assembly has higher antiproliferative activity than free Azi-Ru (IC50 ~10 μM versus ~300 μM in MCF7 604 
cells and IC50 10–20  μM versus ~440 μM in WiDr cells)142.A triplet–triplet annihilation upconversion 605 
(TTA-UC) system for the activation of a [Ru(bpy)2(1,3-bis(methylsulfido)-2-dodecyloxypropane)]2+ 606 
anticancer prodrug candidate has been reported143 (FIG. S1b). The stealth property of liposomes 607 
consisting of the neutral phosphatidylcholine lipids 1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC) 608 
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or 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and 4 mol% sodium N-(carbonyl-methoxy 609 
polyethyleneglycol-2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine (MPEG-2000-DSPE)) is 610 
conferred by the PEG moiety. Both the triplet photosensitizer/donor 611 
[Pd(tetraphenyltetrabenzoporphyrinato)] and the triplet annihilator perylene (or 2,5,8,11-tetra(tert-612 
butyl)perylene) are hydrophobic and localize in the lipid bilayer. After irradiation with red light in the 613 
phototherapeutic window, triplet–triplet energy transfer occurs between the sensitizer/donor and 614 
annihilator, followed by a TTA-UC between two triplet annihilators in their triplet state. This process 615 
allows for the incident red light to induce emission of blue light from the perylene derivatives. 616 
Furthermore, the photoactivable Ru(II) prodrug is located at the surface of the polymer–lipid hybrid, 617 
because the dodecyl chain in the bis(thioether) ligand allows for its incorporation into the lipid 618 
membrane, leading to the surface being decorated with the Ru(II) complex. After the non-radiative 619 
Förster resonance energy transfer (FRET), the blue light emission does not cause tissue damage but does 620 
induce the loss of the bis(thioether) ligand to afford [Ru(bpy)2(OH2)2]2+, which has anticancer activity. 621 
Of note, this liposome nanomaterial was tested in the practical conditions of a phototherapeutic 622 
operation; the upconverted blue light can be generated by TTA-UC even through >10 mm of chicken or 623 
pig tissue. 624 
 625 
[H1] Covalent conjugation 626 
The major drawbacks of physical encapsulation include the uncontrolled release of a therapeutic agent, 627 
especially the ‘burst’ release (except in the case of polymeric carriers based on pH-responsive or photo-628 
responsive polymers), and the often low amount of Ru complexes that can be loaded into the host. An 629 
alternative strategy involves covalent conjugation of Ru complexes to a polymer to give metallopolymer 630 
prodrug candidates144. The first clinical trials of prodrugs developed using this strategy involved using 631 
the polymer–protein conjugates PEG-L-asparaginase (Oncaspar) and styrene maleic anhydride-632 
neocarzinostatin (Zinostatin Stimalmer) to treat leukaemia or hepatocellular carcinoma, respectively145. 633 
As with physical encapsulation, the Ru complex is temporarily protected by the polymer against reactive 634 
species in the biological medium. This approach enables controlled high loading of Ru complexes into 635 
the metallopolymer and ensures the prolonged release of the therapeutic agent during polymer 636 
biodegradation. Both Ru(II) and Ru(III) complexes have been covalently conjugated to polymers. 637 
Biodegradation can involve degradation of the polymer backbone or first the activation of the Ru(III) 638 
centre (by reduction to Ru(II)) followed by degradation of the polymer backbone. Most of the 639 
metallopolymer candidates discussed above were developed as prodrug candidates that target cancer 640 
cells146-147. Similarly, the Ru complexes physically encapsulated in polymer carriers are principally 641 
investigated in view of cancer therapy. Standard metallopolymer prodrug candidates usually have a 642 
‘polymer–linker–therapeutic agent’ architecture, but additional functionalities can be added to achieve 643 
specific targeting or to create combined therapies. Although not discussed in detail in this Review, 644 
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vectorization of Ru complexes can be achieved by conjugation to biomolecules (such as proteins), an 645 
approach that avoids loss of the Ru complex before the target is reached. Moreover, it provides better 646 
control of the release and makes the stability of the metallopolymer in the circulation higher than that 647 
of physically encapsulated Ru complexes. 648 
 649 
In addition to size, surface charge and biodegradibility, the structure of the metallopolymer is an 650 
important consideration in nanocarrier design. First, a suitable conjugation method is one that ensures 651 
that the covalent link between the polymer and the Ru complex remains intact during the transport of 652 
the carrier but is cleaved in the biological medium for delivery to the target site. The cleavage of the 653 
covalent link activates or reactivates the Ru complex after chemical degradation of the metallopolymer. 654 
For this reason, the use of biodegradable polymers is essential in the preparation of polymer-based 655 
metalloprodrugs, with the degradation rate of the metallopolymer controlling the drug delivery kinetics. 656 
A Ru centre can bind polymers containing N-donor ligands, such as amines or pyridines, or O-donors, 657 
such as carboxylates, in different positions, including at the polymer main chain, terminal groups or 658 
pendant groups. Depending on the number of vacant coordination sites (or sites at which a weakly basic 659 
ligand is present) on a Ru complex, the polymer can be a monodentate or bidentate (or, more rarely, 660 
terdentate) ligand, such that the Ru centre can crosslink polymers. Second, the loading rate and 661 
physicochemical properties of the Ru complex must be carefully selected because covalent conjugation 662 
of the Ru complex with the polymer can affect the complex’s physicochemical properties such as H2O 663 
solubility and/or hydrophilic/hydrophobic balance. Third, functionalities sensitive to external stimuli 664 
can be inserted in the polymer backbone and or pendants or in the Ru centre. Photoresponsive 665 
functionalities are the most popular because they enable precise spatial and temporal control of active 666 
compound release. Various polymeric architectures can be obtained, namely linear or brush 667 
(co)polymers, branched polymers (dendrimers) and supramolecular polymers. Depending on where the 668 
Ru centre is conjugated to the polymer (the backbone, a lateral pendant or the centre of a star polymer), 669 
different synthetic strategies are available and these are covered in the following discussion. 670 
 671 
[H1] Linear and brush metallopolymer prodrugs 672 
The synthesis of linear or brush metallopolymers requires the preparation of functionalized polymers as 673 
macroligands before coordination of the therapeutic Ru agents, which bind the polymer through ligand 674 
exchange or by presenting a reactive functional group on their periphery (FIG. 5). To ensure efficient 675 
self-assembly and to protect the conjugated Ru complex from the biological medium, block copolymers 676 
with hydrophilic and hydrophobic segments are most commonly used for the preparation of micelles. 677 
Therapeutically-relevant Ru agents have been covalently conjugated to the hydrophobic segment, 678 
allowing their placement in the core of the micelle. The functional groups for the coordination of the Ru 679 
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complexes are usually inserted as the final groups in the lateral chains of brush copolymers. These ligand 680 
groups can be strong or weak ligands for Ru. 681 
 682 
[H2] Coordination of Ru to strong donor sites on a polymer 683 
Ru(II) complexes that release diatomic therapeutic gases are the major type of Ru complexes that form 684 
metallopolymers by strong Ru–Lpolymer linkages. The complexes can be activated chemically148-150 or 685 
photochemically136, and the gas molecules are liberated without the complete degradation of the polymer 686 
backbone of a brush copolymer. The ligands for the Ru coordination can be inserted during the monomer 687 
preparation before polymerization. For example, up to 2500 equivalents of a CO-releasing Ru complex 688 
are stored in every micelle of a triblock copolymer featuring a hydrophilic PEG block, a poly(orthinine 689 
acrylamide) block bearing [Ru(CO)3Cl(orthinoate)] moieties and a hydrophobic poly(n-690 
butylacrylamide) block148 (FIG. 5a). The incorporation of CO donors (with 15–37 Ru-based units per 691 
polymer, 4.7–10.3wt% Ru) into micelles with a hydrodynamic diameter of 29–44 nm makes the Ru 692 
complex less susceptible to attack from thiols (such as cysteamine and glutathione) than is free 693 
[Ru(CO)3Cl(glycinato)] (CORM-3, FIG. 1), such that the Ru complexes in the polymer release CO 694 
more slowly. Thus, there is in a substantial reduction in the cytotoxicity of the [Ru(CO)3Cl(amido 695 
acidate)] moiety due to the stealth properties of the PEG block. Moreover, in contrast to free 696 
[Ru(CO)3Cl(glycinato)], the CO-releasing micelles efficiently attenuated lipopolysaccharide-induced 697 
nuclear factor-κB activation in THP-1 Blue cells derived from human monocytes (which are linked to 698 
inflammation)148. In a subsequent study, a pyridine ligand was inserted in the hydrophobic polyvinyl 699 
block to give P(OEGA)-P(4VP-CORM-2) (FIG. 5a)150, a polymer variant of CORM-2. Whereas CO 700 
release was spontaneous in the earlier study, in this study the rate of CO release could be controlled by 701 
changing pH. CO release was rapid in acidic conditions and slower at neutral pH, where the polymer 702 
micelles may form a compact structure in which the CO-donor Ru complexes are more protected inside 703 
the micelle core, preventing fast CO release. Conversely, at acidic pH, the pyridine groups not bound to 704 
Ru tend to be protonated, resulting in a less compact structure in which the Ru centres are more 705 
accessible and liable to release CO. This approach of using a polyvinylpyridine block to construct a 706 
polymeric version of CORM-2 can also be applied to making a polymeric NO-releasing agent featuring 707 
trans-{Ru[1,2-bis(pyridine-2-carboximido)-4,5-dimethylbenzene](Lpolymer)NO} fragments. The 708 
polyvinylpyridine also features cross-linked poly(2-hydroxyethyl methacrylate) (pHEMA) in a 709 
copolymer formed from HEMA and ethyleneglycol dimethacrylate (EDGMA) (synthesized by radical-710 
induced copolymerization)151 (FIG. 5b). In contrast to carriers designed for CO-releasing Ru complexes, 711 
the rapid release of NO is strictly dependent on exposure to UV light (even with a low intensity of 5–712 
10 mW), such that NO release is more controllable151. 150. 713 
 714 
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Functionalized tpy complexes were used as a linker for crosslinking of diblock copolymers of 715 
pentafluorophenyl acrylate (PFA) and 2-(2′,3′,4′,6′-tetra-O-acetyl-β-D-glucosyloxy)ethyl methacrylate 716 
(AcGlcEMA) prepared by reversible addition−fragmentation chain-transfer (RAFT) polymerization152 717 
(FIG. 6). After deacylation, nanoparticles with an average size of 60 nm had a core–shell structure with 718 
the Ru(II) complex as the core and glycopolymers as the shell. The nanoparticles were H2O-soluble 719 
owing to the hydrophilic corona of glycopolymers and showed low cytotoxicity in KB cells.)  These 720 
nanoparticles might therefore be useful as a cellular label for one-photon and two-photon fluorescence 721 
bioimaging. Coordination of Ru on labile ligands  722 
A polymer decorated with weakly basic ligands can serve as a scaffold for a triggered release or triggered 723 
activation of a metallopolymer prodrug, wherein the weak Ru–Lpolymer bonds are readily cleaved in a 724 
controlled manner. The activation can be effected by various stimuli, such as a change in the biological 725 
medium, hydrolysis or light. 726 
 727 
As described above for physical encapsulation, natural biodegradable polymers have also been used as 728 
delivery vehicles for Ru complexes, whose release is activated by hydrolysis of the polymer in the 729 
biological medium153-154. The linear polysaccharide chitosan is one such biodegradable polymer, and the 730 
primary amine in each monomer can serve as a functional handle to which a Ru centre can be appended. 731 
For example, the amine can be decorated with caffeic acid as a ligand or undergo a Schiff base 732 
condensation to afford an imine ligand153-154 (FIG. 6a). The conjugation of caffeic acid-modified chitosan 733 
to the {Ru(p-cym)Cl}+ fragment induces a change of backbone chitosan structure152 to give 30–120 nm 734 
particles. Anticancer activity may be realized if hydrolysis occurs to release the active dimer {[(η6-735 
arene)Ru]2(η2-OH)3}+. Likewise, the Schiff base is also not a strong ligand for Ru(III), which can be 736 
released so as to afford antibacterial activity against Gram-positive bacteria, such as B. subtilis, S. 737 
aureus, and Gram-negative bacteria, such as E. coli, K. pneumoniae and P. aerugonisa154. 738 
 739 
In photoactivated chemotherapy (PACT), a non-toxic or minimally toxic prodrug candidate becomes 740 
more toxic after light irradiation. This photo-release strategy is based on masking the functional groups 741 
involved in the toxicity using a photo-cleavable motif. As in photodynamic therapy (PDT), the use of 742 
photo-responsive cages as carriers is of great interest owing to the spatial and temporal control of 743 
activation.  744 
 745 
Inspired by studies of Ru(II) polypyridyl photocages,155-156 two studies reported the preparation of 746 
different photoresponsive platforms based on metalloblock copolymers for combined PACT and PDT. 747 
Both studies made use of an active Ru fragment (FIG. 7a) bound to the polymer through a weakly 748 
coordinating 4-[(6-hydroxyhexyl)oxy]benzonitrile residue157-158, such that red light cleaves the Ru–749 
Lpolymer bond to release the anticancer drug candidate and generate 1O2 to inhibit cancer cell growth. In 750 
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the first study157, {Ru(2,2′-biquinoline)2}2+ binds up to two nitriles, each being at the end of a long 751 
organic chain terminated by a PEG chain that confers stealth properties. Here, red light irradiation causes 752 
loss of the nitrile to generate {Ru(2,2′-biquinoline)2(OH2)2}2+. In the second study, a single hydrophobic 753 
photolabile Ru complex was anchored in the main chain on the block copolymer.158 Depending on the 754 
size of each of its constituent blocks, the amphiphile can assume different mesostructures: micelle, 755 
hollow sphere and large compound micelle. It is the micelles, of diameter 12 nm (41wt% Ru loading) 756 
that had the highest cellular uptake and anticancer activity,158 decreasing HeLa cell viability by 73% 757 
after red-light irradiation.  758 
 759 
 760 
The position of the coordination of the Ru complex in the polymer main chain or lateral chains, as well 761 
as its molecular weight, were crucial for the structure and the size of the nanoparticles as well as cellular 762 
uptake. For these two metallopolymers, the Ru complexes were not only used as photoactivators but 763 
were also responsible for the bioactivity of the metallopolymer.  764 
 765 
Related to the above design is a hydrogel based on biocompatible hyaluronic acid hydrazide polymer 766 
chains, which can be crosslinked with [Ru(bpy)2(3-pyridinaldehyde)2]2+ in a Schiff base condensation 767 
that affords a photodegradable linkage (FIG. 7b)159. The Ru complex function primarily as a 768 
photoactivator and remains linked to one polymer chain after photoactivation. This metallopolymer gel 769 
can be loaded with bacterial β-lactamase TEM1 as a model protein cargo, the release of which occurs 770 
after photodissociation of a Ru–Npyridine bond. The photodelivery of TEM1 from microgel particles 771 
(average diameter 74±6 μm) can occur even with low doses of visible light, with complete degradation 772 
of the particles occurring over 60 s at 10 mW cm−2. Moreover, the resulting metallopolymer containing 773 
the imine of [Ru(bpy)2(3-pyridinaldehyde)(OH2)]2+ could act as a ROS photogenerator. 774 
 775 
[H1] Linear and star metallopolymer prodrugs 776 
Ru(II) polypyridyls have been used as the central core in the preparation of linear or star 777 
metallopolymers, the choice of which depends on the number of functionalized ligands on the Ru centre. 778 
The two strategies for the synthesis of linear and star metallopolymers developed so far, convergent and 779 
divergent, are now described (FIG. 8). 780 
 781 
[H2] Convergent strategy 782 
The convergent strategy for the preparation of star metallopolymer drugs is based on the prior synthesis 783 
of polymers as macroligands followed by the coordination of the Ru centre by ligand exchange. For 784 
example, bpy ligands are readily functionalized with biodegradable polyesters160-162 using ring-opening 785 
polymerization of cyclic ester monomers. PCL (FIG. 8A) is amenable for incorporation into a drug 786 
 23 
 
carrier owing to its low degradation rate and its permeability to small molecules studies160-161. The 787 
polymerization of ε-caprolactone by subcritical CO2 processing gives biodegradable open cell foams, 788 
which contrasts the otherwise semicrystalline microstructure of poly(ε-caprolactone) and enabled its use 789 
for  culturing cells 161 The same convergent strategy was also used to develop a polymer-containing 790 
analog of the anticancer drug candidate TM34 ([Ru(C5H5)(bpy)(PPh3)]OTf) (FIG. 8A). The polymer 791 
drug had an IC50 in the micromolar range in human MCF-7 and MDA-MB-231 breast cancer cell lines 792 
and the A2780 ovarian adenocarcinoma cell line162.  793 
 794 
 795 
[H2] Divergent strategy	796 
The divergent strategy uses a Ru complex as a metalloinitiator for polymerization. Polymerization by 797 
ring-opening polymerization or radical polymerization is carried out after pre-assembly of the Ru 798 
complexes (FIG. 8b), which have end reactive groups that enable the initiation of polymerization. 799 
 800 
Luminescent [Ru(bpy)3]2+-centred star block copolymers with a hydrophobic PLA core and a 801 
hydrophilic poly(acrylic acid) corona (FIG. 8b) have served as a preliminary model for imaging 802 
probes163. In particular, a Ru complex was used as a metalloinitiator for 4-(dimethylamino)pyridine-803 
catalysed ring-opening polymerization of lactide, followed by atom transfer radical polymerization to 804 
introduce poly(tert-butyl)acrylate chains. The esters were finally hydrolysed using Me3SiI to give a 805 
H2O-soluble poly(acrylate) corona. The same divergent strategy was used to synthesise a star-shaped 806 
[Ru(bpy)3]2+-centred poly(ethyleneimine), where the polycationic PEI polymer is used for gene 807 
delivery164-165 by electrostatic binding of the carrier with DNA, thereby protecting it against cleavage by 808 
nucleases166. As an alternative to PEG, a biocompatible polyoxazoline was used to confer stealth 809 
properties to the metallopolymer drug. The living cationic ring-opening polymerization of 2-ethyl-2-810 
oxazoline followed by an acid hydrolysis of amide groups provided protection for the hexafunctional 811 
[Ru(bpy)(CH2Cl)2)3]2+ core (FIG. 8b). The system seems to be limited for imaging properties and was 812 
first tested for the transfection of the LNCaP prostate cancer cell line. The entrapment of DNA in the 813 
polyoxazoline was comparable to that by Ru-free linear cationic polymers of a higher molecular weight 814 
and was more efficient than that by Ru-free branched PEI of a similar molecular weight. 815 
 816 
 817 
A NO-donor salen ligand Ru complex functionalized with two terminal styrene pendants were 818 
incorporated into the main polymer chain during the radical polymerisation of 819 
ethyleneglycoldimethacrylate, in the presence of azobisisobutyronitrile as radical initiator, for the 820 
preparation of porous particles (75 μm or 125 μm in diameter and an average pore diameter of 60 μm 821 
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(FIG. 8Bb).167 After photoirradiation at 370 nm, this porous material released NO to proteins during in 822 
vitro tests on equine skeletal muscle myoglobin. 823 
 824 
[H1] Ru centre-rich metallopolymers 825 
In the synthesis of metallopolymers, it is sometimes difficult or impossible to control the loading of the 826 
Ru complexes, except in the case of a star-shaped architecture with a Ru-based central core. One method 827 
involves covalent conjugation of Ru complexes to well-defined architecturally branched polymers. The 828 
globular or spherical structure of these polymers — known as dendrimers — represent an alternative to 829 
using polymeric nanoparticles in delivery systems. However, most dendrimer backbones are not easily 830 
biodegradable, such that Ru complexes are almost always covalently conjugated to the end of the arms 831 
constituting the dendrimer shell and not to the dendrimer core (only one example exists of physical 832 
encapsulation of a Ru complex in a dendrimer)168. The charge on Ru complexes conjugated to a 833 
dendrimer shell determines the conjugate’s H2O solubility and can be adjusted to induce selective 834 
accumulation in cellular compartments and thereby tune toxicity. In most cases, the strategies used to 835 
synthesize standard polymers have also been used for the conjugation of Ru complexes. The ligand units 836 
are inserted as terminal groups on branched chains of the dendrimer shell, after which they bind Ru 837 
centres by displacing weakly bound ligands169-174. 838 
 839 
In contrast to linear polymers or those with few crosslinks, assemblies based on dendrimers have a dense 840 
architecture, which probably slows the release of encapsulated Ru complexes substantially. However, a 841 
direct relationship between chemical structure and the bioactivity of dendrimers has yet to be 842 
rationalized. Dendrimers are among the smallest drug delivery carriers, with sizes in the range of tens 843 
of nanometers, although a direct size comparison between various types of dendrimers is difficult owing 844 
to different molecular packing. Hydrogen bonding in polyamide dendrimers increases the density of 845 
globular dendrimers with higher generations, whereas polyamine chains maintain greater flexibility 846 
leading to less dense globular dendrimers. To study the effects of dendrimer size on cytotoxicity, a large 847 
library of first- to fourth-generation Ru(II) arene complexes based on the diaminobutane (DAB)-848 
poly(propyleneimine) dendrimer scaffold was generated169-172 (FIG. S2). Dendrimer toxicity generally 849 
increased as a function of its size175 but, surprisingly, increased cytotoxicity was observed for each group 850 
of larger dendrimers (third and fourth generations), demonstrating that cytotoxicity is clearly linked to 851 
metallodendrimer size. Each drug candidate featured a terminal aromatic group conjugated to an imine 852 
functionality. The aromatic substituents minimize and counterbalance the effect of the imine groups, 853 
which were susceptible to hydrolysis in the final products {[Ru(arene)Cl]n(dendrimer ligand)}m+. In each 854 
case, replacing the Cl− ligands with PTA affords cationic complexes with lower IC50 values in A2780 855 
and A2780 cisR cell lines, owing to the interaction of PTA with DNA172. The 4th generation compound 856 
with the N,O bidentate neutral ligand and p-cymene ligand (FIG. S2) with 32 arms had the highest 857 
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cytotoxicity (IC50 = 0.8 μM in A2780 cells, IC50 = 2.7 μM in A2780cisR cells and IC50 = 2.6 μM in 858 
healthy HEK cells. Preliminary biological studies showed that the insertion of ferrocenyl group 859 
conjugated on the Ru complex (FIG. S2) reduced the proliferation of A2780 and A2780cis R cells by 860 
>50% (IC50 <5 μM at equi-iron concentrations of 5 μM) and substantially reduced the proliferation of 861 
SISO human cervix cancer cells, LCLC-103H human lung cancer cells and 5637 bladder cancer cells in 862 
vitro172. 863 
A dendritic system based on a pentaerythritol core bearing the pendant tpy (for the coordination of Ru 864 
centre) and functionalized with 1,2-dicarba-closo-dodecaborane units (FIG. S2) has been used in 865 
BNCT176-177. This promising dendrimer has yet to be biologically tested. [ 866 
 867 
[H1]  Concluding remarks 868 
The use of Ru complexes in medicinal chemistry has increased substantially in the past decade, 869 
encouraged by clinical trials of NAMI-A, KP1039 and TLD-1433. Most Ru complexes discussed in 870 
this Review are envisioned for the treatment of various cancers using chemotherapy and/or other 871 
therapies, such as PDT or BNCT. However, research on the encapsulation of Ru complexes in polymeric 872 
carriers is still in its infancy and must compete with research on the encapsulation of Pt-based drugs196-873 
197, which were discovered earlier and dominate the chemotherapeutics market. In contrast to Pt-based 874 
drugs, two strategies, developed in parallel, exist for the encapsulation of Ru complexes — physical 875 
encapsulation and covalent conjugation. Commercially available or easily accessible polymers are 876 
typically chosen for the encapsulation of Ru compounds. Although the synthetic approaches are clear, 877 
the relationship between the properties of the polymer and the properties of the final polymer-878 
encapsulated complex has rarely been clarified or linked to the delivery properties of these complexes 879 
in biological media. Physical encapsulation remains the most common strategy to deliver Ru complexes 880 
because it is simpler and faster than covalent conjugation. However, the structure of these physically or 881 
covalently bound speciesdvances towards more sophisticated architectures comprising a time and space 882 
controlled release of biological active Ru complex using an external stimulus.  883 
 884 
For the physical encapsulated Ru complex delivery systems, the stability of the carrier is an important 885 
consideration for improved drug delivery and prolonged storage of nanocarriers. The effect of 886 
nanocarrier shape on the efficiency of drug delivery has been only lightly studied198. Nanocarriers used 887 
for the physical encapsulation of Ru complexes are most often spherical; tubular nanocarriers that can 888 
deliver metal complexes and specifically target cellular compartments are rare. The functionalization of 889 
inorganic nanotubes (such as carbon nanotubes) is difficult, such that biodegradable organic nanotubes 890 
derived from alginate and chitosan199 appear better vehicles for the delivery of biologically active Ru 891 
complexes. Another emerging approach is the preparation of delivery systems containing two anticancer 892 
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drugs for combination therapy, such as chemotherapy combined with PDT or BNCT. Ru complexes 893 
have already been incorporated on the surface of Au nanomaterials or C nanotubes as photothermal 894 
agents55. Physical encapsulation of Ru complexes in biocompatible photothermic polymers200, such as 895 
polyaniline or melanine derivatives, is another potential delivery system for combined photothermal 896 
therapy and chemotherapy. 897 
 898 
Overall, research into the encapsulation of Ru complexes will undoubtedly continue to develop in the 899 
future with the expected increase in the number of FDA-approved Ru-based drugs. Owing to the 900 
structural variety of polymers and Ru complexes, new delivery platforms will certainly be developed in 901 
the coming years for various biological applications beyond their conventional use as anticancer 902 
therapies.  903 
 904 
 905 
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Display items 1387 
Box 1| The mechanisms of action of Ru complexes 1388 
 1389 
DNA damage  1390 
Cellular dysfunction in disease or cancer can result from DNA damage (such as autoxidation in air, 1391 
disproportionation or hydrolysis). The proliferation rate in cancer cells is high and is regulated by the 1392 
cell cycle and DNA replication. Therefore, damaged DNA is a key target for Ru-based anticancer drug 1393 
 40 
 
candidates and is the major mechanism by which many FDA-approved metallo-therapeutics (such as 1394 
Pt-based drugs) and organic oncology drugs (such as doxorubicin and gemcitabine) operate. Ru 1395 
complexes with planar aromatic ligands selectively bind to DNA by covalent and/or non-covalent 1396 
modes. Covalent binding is irreversible and results in the formation of DNA–Ru complex adducts that 1397 
distort the DNA backbone and disrupt replication and transcription, leading to cell death (as observed 1398 
for (η6-arene)RuII complexes, such as RM-175 (FIG. 1)). Non-covalent binding is usually reversible and 1399 
includes interactions such as electrostatic binding, intercalation and groove binding, as observed for 1400 
RAPTA-C (FIG. 1). Most cationic RuII complexes have one or more planar aromatic ligands, which can 1401 
intercalate between adjacent base pairs in DNA. Distortion of the double helix caused by these ligands 1402 
can inhibit or completely block transcription and replication.  1403 
	1404 
DNA metabolism	1405 
A set of proteins are responsible for genome integrity. Topoisomerase II is the principal enzyme in the 1406 
cell nucleus involved in DNA replication, transcription, recombination and sister chromatid segregation 1407 
during mitosis179. Selective inhibition of topoisomerase II can inhibit neoplastic cell proliferation and 1408 
possibly induces apoptosis through DNA fragmentation by the accumulation of permanent double strand 1409 
breaks. For example, [RuCl2(C6H6)(Me2SO)] is a topoisomerase II inhibitor that covalently binds to 1410 
DNA by ionic interaction of the RuII centre with DNA nucleobases180. KP1019 (FIG. 1) localizes in the 1411 
cytoplasm and binds efficiently to serum proteins181and interferes with the P-glycoprotein182.  1412 
 1413 
The antioxidant glutathione (GSH) protects cells from reactive oxygen species (ROS), UV radiation and 1414 
heavy metal toxicity. In its reduced form, GSH is readily oxidized to glutathione disulfide (GSSG) by 1415 
the enzyme glutathione S-transferase (GST). Overexpression of GST by tumour cells is implicated in 1416 
drug resistance, and an organometallic (p-cymene)RuII complex conjugated to ethacrynic acid, a GST 1417 
inhibitor, efficiently inhibits GST and is toxic to a GST-overexpressing cancer cell line183.  1418 
Protein kinases 1419 
Protein kinases are phosphorylating enzymes that have important roles in signalling pathways 1420 
associated with intercellular uptake and cell proliferation. The identification of novel kinase inhibitors 1421 
is important for the development of new anticancer therapies. The major strategy for the design of new 1422 
Ru complexes that target protein kinases involves the use of substitutionally inert RuII centres 1423 
coordinated to a bioactive ligand. The resulting rigid, stable 3D structures are extremely selective 1424 
protein kinase inhibitors184 (DW1/2, FIG. 1).  1425 
Box 2 | Methods of targeting tumours	1426 
The pH in cancerous or inflamed tissues is usually abnormally low (pH = 5–6 in the extracellular 1427 
medium) and local hyperthermia (around 42 °C). Many tumours have a leaky vasculature and lack or 1428 
have altered lymphatic drainage. The vascular endothelium in tumours proliferates rapidly and 1429 
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discontinuously, which results in a disorganized vasculature with a large number of ‘open’ intercellular 1430 
junctions (0.2–1.2 μm in diameter, compared with <10 nm in normal vessels). These biological 1431 
characteristics are exploited to design efficient drug delivery carriers, such as anticancer prodrugs. High 1432 
molecular weight molecules, such as polymers and particles of diameter ~20–500 nm (except for 1433 
‘stealth’ carriers), passively accumulate in the tumour area. This ‘passive targeting’, termed the 1434 
enhanced permeability and retention (EPR) effect71-73, is possible because these molecules can cross the 1435 
tumour endothelial barrier through the open junctions of the leaky vasculature and accumulate because 1436 
of insufficient lymphatic drainage from the tumour. Of note, ‘targeting’ in this context does not refer to 1437 
a specific interaction between a target molecule and a cellular receptor but instead refers to the selective 1438 
accumulation of the nanocarrier in tumour tissues rather than in healthy tissues — the drug concentration 1439 
in tumour tissues can be up to 10–100-fold higher than in healthy tissues185. The EPR effect allows the 1440 
use of a lower drug dose and increases the efficacyof the biologically active compound, thereby limiting 1441 
adverse effects. The diameter of polymer particles does not remain constant during the delivery process 1442 
and tends to decrease over time. Consequently, the design of fairly large nanocarriers (final diameter 1443 
<100 nm to avoid removal from the blood and accumulation in the liver and spleen) with high Ru loading 1444 
is preferred186. Nanoparticles of intermediate diameter (10–100 nm) avoid renal clearance and have 1445 
prolonged circulatory times compared with nanoparticles <10 nm in diameter), owing to their slow 1446 
transport across the endothelium187. Despite their small size, nanoparticles <20 nm in diameter show 1447 
better tumour penetration188-190 because they can pass through the leaky capillary walls in tumour tissue 1448 
and also return to the bloodstream by diffusion. It is hypothesized that nanoparticles 10–20 nm in 1449 
diameter can re-enter the tumour tissue without being eliminated by any clearance mechanisms191, which 1450 
might explain their efficient accumulation in tumour tissues. The contradictory results in these studies 1451 
suggest that the accumulation of nanoparticles in the tumour is not only dependent on their size. 1452 
 1453 
To obtain an efficient delivery system, the physicochemical properties of a nanocarrier, such as the 1454 
biocompatibility, hydrophilicity/hydrophobicity balance, carrier size and surface charge of the polymer 1455 
can be adjusted during nanocarrier preparation. All of these features affect the non-specific interactions 1456 
of polymers with cells of reticuloendothelial system (RES) in the circulation and interactions of 1457 
polymers with various components inside tumour tissues. The uptake of nanocarriers, especially those 1458 
that are hydrophobic, by the RES is predominantly through phagocytosis by macrophages, which is 1459 
initiated by the adsorption of various serum proteins termed opsonins. The EPR effect is time-dependent 1460 
and requires adequate circulation stability for at least several hours to be efficient. To increase their 1461 
circulation time and protect them from opsonization, carriers can be coated with a sufficiently thick and 1462 
dense layer of hydrophilic polymers, such as PEG or other polymeric glycols, or synthetic glucuronic 1463 
acid derivatives or polyphosphoramides to form ‘stealth carriers’ 191-194. Optimization of the 1464 
hydrophilic/hydrophobic balance of a nanocarrier is the primary factor affecting the efficiency of drug 1465 
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delivery to tumour tissues. Generally recognized as safe by the FDA, PEG is the standard polymer for 1466 
the preparation of stealth carriers owing to its biocompatibility91 and low toxicity195. The targeting of 1467 
nanocarriers to tumour tissues is not only limited to the EPR effect but can also involve pH-dependent 1468 
hydrolytic activation in the tumour tissue or redox processes in the cytosol. Furthermore, molecules such 1469 
as peptides, antibodies or carbohydrate units, can be attached to the surface of nanocarriers to increase 1470 
tumour specificity. The choice of molecule depends on the mechanism of the transported drug; for 1471 
example, chemotherapeutic agents have various mechanisms of action, such as DNA alkylation 1472 
(cisplatin) or intercalation (doxorubicin), or inhibition of microtubules (taxanes), metabolic processes 1473 
(gemcitabine) or angiogenesis (endostatin). 1474 
 1475 
Figure 1 | Representative Ru complexes with medicinal potential. A variety of Ru species — from 1476 
RuII to RuIV, cationic to anionic — have been designed for medicinal applications. The complexes were 1477 
intended as agents for chemotherapy3-11 and photodynamic therapy12-15, as well miscellaneous based on 1478 
their vasodilation, antioxidant, anti-inflammatory, anti-microbial and anti-malarial properties.16,38, 119, 124, 1479 
136, 149-150 1480 
Figure 2 | Methods to encapsulate Ru complexes in polymers. Ru complexes can have different 1481 
charges and are usually incorporated into polymers using either covalent conjugation or physical 1482 
encapsulation. The former is irreversible, while the latter process is typically reversible such that the Ru 1483 
species can often leach from the assemblies. 1484 
 1485 
Figure 3 | Some prominent biodegradable polymers. Chitosan is a linear polymer of an aminosugar, 1486 
which can be protonated under physiological conditions. In contrast, alginate is also a sugar derivative 1487 
but is an anionic polymer. Poly(glycolic acid) (PGA), poly(lactic acid) (PLA) and the corresponding 1488 
copolymer poly(lactid-co-glycolic)acid (PLGA), as well as poly(ε-caprolactone) (PCL) are all 1489 
biodegradable polyesters. 1490 
  1491 
Figure 4 | Synthetic strategies for Ru-conjugated polymer prodrug candidates. a | The convergent 1492 
synthesis approach involves coordinating Ru to a preformed macromolecular organic ligand. b | 1493 
Alternatively, the divergent strategy uses a Ru complex with strongly bound ligands as a metalloinitiator 1494 
for polymerization. 1495 
 1496 
Figure 5 | Photoactivable nanocarriers. a | RuII(CO)3 fragments serve as sources of CO in hydrolyzable 1497 
polymers that are activation by hydrolysis. b | Light activation can cause a Ru–NO bond to break and 1498 
release NO or  release an anticancer Ru drug that generates 1O2157. The toxicity of this metalloprodrug 1499 
principally comes from the photoactivation of Ru drug candidate remaining coordinated in the polymer 1500 
chain. 1501 
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 1502 
Figure 6 | Ru conjugates of chitosan. a | Caffeic acid-modified chitosan can bind Ru through its 1503 
catechololate moiety. The Ru moiety can undergo hydrolysis to afford the bioactive dimer {[(η6-1504 
arene)Ru]2(η2-OH)3}+. b | A chitosan Schiff base can serve as a ligand for Ru in a polymer drug 1505 
candidate with antibacterial activity. 1506 
 1507 
Figure 7 | Photo-triggered aquation of Ru–polymer conjugates unmasks reactive moieties. a | 1508 
Displacement of nitrile ligands with H2O affords reactive Ru polypyridyl aquos that can sensitize the 1509 
formation of 1O2. b | Here, the Ru serves as a photolabile cross-link between polymer chains in a gel. 1510 
Breaking this link can enable the release of cargo such as proteins. 1511 
 1512 
Figure 8 | Synthesis of Ru complexes bearing ligands with two (up to six) polymer chains. A | The 1513 
convergent synthesis method can afford RuII species with bpy ligands difunctionalized with polymer 1514 
chains. Ba | Ru complexes bearing reactive groups at their periphery can serve as initiators from which 1515 
ring-opening polymerization can occur. Bb | A [Ru(salen)(NO)Cl] derivative with pendant vinyl groups 1516 
is an initiator for radical polymerization. 1517 
 1518 
